177Lu-FAPI-46治疗复发或难治性癌症的可行性与治疗潜力初步研究
本研究评估了177Lu-FAPI-46在晚期不可手术或常规治疗难治性癌症患者中的可行性、安全性和剂量学。21例患者中18例接受肽靶向放射性核素治疗(PTRT),共36个周期,中位每周期活度3.7 GBq。治疗耐受性良好,剂量学数据显示全身、肝、肾、脾的中位吸收剂量分别为0.026、0.136、0.886、0.02 mGy/MBq。
要点
- 177Lu-FAPI-46在多种晚期癌症中初步显示可行且耐受性良好。
- 每周期中位活度3.7 GBq,中位2个周期,间隔4-6周。
- 肾脏中位吸收剂量最高(0.886 mGy/MBq),需关注剂量学。
核心结论
- 初步研究表明177Lu-FAPI-46用于不同侵袭性肿瘤的PTRT具有潜在可行性和安全性,并有助于确定2期研究的合适活度。
研究设计与样本
- 前瞻性初步研究,纳入21例晚期不可手术或常规治疗难治性癌症患者(11女10男,中位年龄50岁,范围6-79岁),采用临床与统计专家组合设计递增活度(1.85-4.44 GBq/周期),周期间隔4-6周。
主要发现
- 21例中18例接受PTRT,共完成36个周期;中位周期数2,每周期中位注射活度3.7 GBq。
- 全身、肝、肾、脾的中位吸收剂量分别为0.026、0.136、0.886、0.02 mGy/MBq,范围分别为0.023-0.034、0.001-0.2、0.076-1.39、0.002-0.2 mGy/MBq。
- 几乎所有患者治疗耐受性良好。
关键数值与推荐
- 采用美国国家癌症研究所不良事件通用术语标准4.03版评估肽靶向放射性核素治疗(PTRT)相关毒性。
临床怎么用
- 对于晚期难治性癌症患者,可考虑177Lu-FAPI-46 PTRT,但需基于剂量学数据关注肾脏等器官的吸收剂量。
局限性
- 为初步研究,样本量小(21例),需进一步2期研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Fibroblast activation protein (FAP) is a member of the serine protease family and has a high expression in the stroma of approximately 90% of epithelial malignancies. The present investigation aimed to assess the feasibility, safety, and dosimetry data of 177Lu-FAPI-46 in diverse malignancies. PATIENTS AND METHODS: Patients with advanced cancers with nonoperable tumors, or tumors refractory to conventional therapies, were enrolled. Treatment included escalating doses of 177Lu-FAPI-46 (1.85-4.44 GBq) per cycle using a combination of clinical and statistical expertise design, and intervals of 4 to 6 weeks were considered between the cycles. Biodistribution and dosimetry were examined by whole-body scans. We applied the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 to measure peptide-targeted radionuclide therapy (PTRT)-associated toxicity. RESULTS: A total of 21 patients (11 females and 10 males) with a median age of 50 years (range, 6-79 years) were investigated. Of 21 participants, 18 cases were selected for PTRT. Overall, 36 PTRT cycles were performed. The median number of PTRT cycles and the median injected amount of activity in each cycle were 2 and 3.7 GBq, respectively. The dosimetric analysis revealed median absorbed doses of 0.026, 0.136, 0.886, and 0.02 with ranges of 0.023-0.034, 0.001-0.2, 0.076-1.39, and 0.002-0.2 mGy/MBq for the whole body, liver, kidneys, and spleen, respectively. The therapy was well tolerated in almost all patients. CONCLUSIONS: The findings of this preliminary investigation might indicate the potential feasibility and safety of PTRT using 177Lu-FAPI-46 for different aggressive tumors. Moreover, the current study could be beneficial in determining the suitable amount of activity for a phase 2 study.
引用
- Assadi M, Rekabpour SJ, Jafari E, et al. Feasibility and Therapeutic Potential of 177Lu-Fibroblast Activation Protein Inhibitor-46 for Patients With Relapsed or Refractory Cancers: A Preliminary Study. Clin Nucl Med. 2021. PMID: 34269729. doi:10.1097/RLU.0000000000003810
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。